Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: Case series and review of the literature

High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: A literature review

“…A review of all case series reporting SLNB in cSCC is detailed in Table IV. 13,18,28,[41][42][43][44][45][46][47][48][49][50][51][52] Our systematic review identified an overall positive rate for SLNB of 13.9% (32 of 231 patients) and a false-negative rate of 4.6% (10 of 215 patients) in cSCC. The authors usually stated that patients had high-risk factors for lymph node involvement.…”

“…[15][16][17] Numerous studies have documented high-risk factors associated with poor outcomes (Table I). [8][9][10]13,15,[17][18][19] Based on a combination of consensus and low level evidence, the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th Edition (AJCC-7), identified 5 high-risk features. 20 Patients with 2 or more high-risk features were categorized as a T2 primary irrespective of size.…”

Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma

“…7,11 This is well established in the staging of melanoma, but is still debated in the staging of cSCC though there are many studies suggesting that it has high sensitivity and NPV. 1,13 Selected lymph node dissection for patients with cSCC remains unproven. Therefore, a minor surgical procedure such as sentinel node dissection is a possibility, as, in theory, identifying the lymph node that drains the area of the tumor site seems reasonable, because spread to the local node basin can occur.…”

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

“…Although the use of sentinel lymph node biopsy (SLNB) has been investigated in several studies, there are no conclusive data on its prognostic information or the possible therapeutic value [69,70]. A meta-analysis of 19 reports on SLNB in 130 patients with non-anogenital cSCC identified a positive SLN in 12.3% of patients with tumours >2 cm in diameter [71].…”